 Immutep Limited NASDAQ: IMMP has completed all the necessary steps with the FDA and has received institutional review board approval to commence its Phase 2b TACTI-003 trials in the U.S. Patient recruitment for the trial will begin in Q3 of 2021. It will evaluate the Companys lead product candidate, eftilagimod alpha efti or IMP321, in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab as first-line therapy in approximately 154 patients with Head and Neck Squamous Cell Carcinoma HNSCC. 